Pharmacologic Treatment Options for Binge-Eating Disorder
For adults with binge-eating disorder who prefer medication or have not responded to psychotherapy alone, use either an antidepressant or lisdexamfetamine. 1
Treatment Algorithm
First-Line Approach
Psychotherapy remains the primary treatment—specifically eating disorder-focused cognitive-behavioral therapy or interpersonal therapy 1. However, medication should be considered in two specific scenarios:
- Patient preference for medication over psychotherapy
- Inadequate response to psychotherapy alone
Medication Options
When pharmacotherapy is indicated, you have two evidence-based choices 1:
1. Lisdexamfetamine
- The only FDA-approved medication specifically for binge-eating disorder 2
- Reduces both binge eating frequency and associated weight 3
- Typical dosing follows ADHD guidelines (start low, titrate to effect)
- Important caveat: This is a stimulant with abuse potential—screen for substance use history and monitor appropriately
2. Antidepressants
- SSRIs are the most studied class
- No specific agent or dose is mandated by guidelines, but extrapolating from bulimia nervosa data suggests higher doses may be needed (e.g., fluoxetine 60 mg daily for bulimia) 1
- Consider patient's comorbid conditions: citalopram, fluoxetine, sertraline, duloxetine, or venlafaxine work well if anxiety or depression coexist 3
Emerging Options (Off-Label)
While not included in the 2023 APA guidelines, newer evidence suggests additional agents worth considering:
GLP-1 Receptor Agonists (e.g., liraglutide, semaglutide)
- Emerging data shows consistent reductions in binge eating behaviors and significant weight loss (-3 to -24 kg) 4
- Particularly useful when obesity is a prominent comorbidity
- Primary side effects are gastrointestinal; no new psychiatric safety concerns identified 4
- Clinical pearl: These agents address both the eating disorder and metabolic consequences simultaneously 5
Topiramate
- Evidence supports efficacy for reducing binge frequency 3
- Not FDA-approved for BED but recommended by some experts 3
- Major limitation: Cognitive side effects (word-finding difficulties, concentration problems) often limit tolerability
Naltrexone-Bupropion Combination
- Shows promise for both weight reduction and binge eating in patients with elevated BMI 5, 3
- Dual mechanism: reduces reward-driven eating (naltrexone) and increases energy expenditure (bupropion)
Critical Clinical Considerations
Avoid Weight-Gaining Medications
When treating comorbid conditions in BED patients, actively avoid medications that promote weight gain 3:
- Atypical antipsychotics (olanzapine, clozapine)
- Mirtazapine
- Tricyclic antidepressants
- Valproate
Since obesity is a frequent consequence of BED, weight-neutral or weight-reducing agents should be prioritized.
Strength of Evidence Nuance
The APA guideline rates the medication recommendation as 2C (suggestion with low-quality evidence), reflecting greater uncertainty compared to the psychotherapy recommendation (1C) 1. This means:
- Benefits still outweigh harms
- Patient values and preferences should heavily influence the decision
- The balance is less clear than for psychotherapy
When to Use Medication
Consider pharmacotherapy when:
- Patient explicitly prefers medication to therapy
- Psychotherapy has been tried for at least 6 weeks with minimal response (extrapolating from bulimia nervosa guidelines) 1
- Significant comorbid conditions (ADHD, depression, obesity) warrant treatment that could simultaneously address BED
- Access to specialized eating disorder psychotherapy is limited
Monitoring
Regardless of agent chosen:
- Track binge frequency (primary outcome)
- Monitor weight and metabolic parameters
- Assess for psychiatric side effects
- Evaluate treatment response by 6-8 weeks; if inadequate, consider switching agents or adding psychotherapy